Uncompromising
Quality, Delivery and Patient-Centricity
Avant Health leadership has built a track record of thought leadership and partnerships over the past two decades that are rooted in uncompromising quality of research, delivery, and advisory services. Patient-centricity and client-centricity are in the core of Avant Health’s organizational culture that drives our actions every day.
Avant Health advises C-suite stakeholders and functional heads within the public sector, life sciences and healthcare industry, sharpening their public, corporate, commercial and scientific strategy formulation and execution, accelerating their path to success.
DEDICATED TO YOUR BUSINESSFocus on
Relationships and Unmet Needs
Avant takes a personalized approach to engagements, curating a highly specialized team of experts and program managers to meet the specific needs of public sector and private sector stakeholders. As we aim to deliver on our objectives, focus always remain on stakeholder relationships and meeting the unmet needs. We take pride in putting patients/consumers first.
CHIEF EXECUTIVE
Siva Narayanan, Ph.D.
A strategist and leader with over two decades of experience in formulating patient-centric commercialization and access strategies through market/stakeholder focus, research excellence and strategy support. Proven leader and team builder with business and clinical backgrounds.
Siva built a strong career and leadership in commercial/medical strategies, market access, value/evidence and health policy within Pharma/Biotech industry through tenures at PTC Therapeutics (orphan diseases), Human Genome Sciences/GSK (orphan disease & immunology), BMS (oncology & immunology) and Merck & Co. (CNS, ID & respiratory) covering US & Ex-US segments. At PTC, as VP and Global Head, led market access, pricing and value creation department covering Americas, Europe, MENA & APAC.
In the strategy consulting arena, most recently, Siva was President and Global Head of Pointe Health/Pointe Advisory, a strategy consulting and competitive intelligence firm. Previously, Siva held SVP roles at DRG, TNS Healthcare/Kantar and Ipsos Healthcare leading relevant divisions and client strategies to help clients create commercial and scientific strategies and patient access solutions, articulate product value propositions and achieve optimal access in the U.S and Ex-U.S. Within healthcare provider sector, Siva led clinical and strategic evaluations across a spectrum of LTC services at Beverly Enterprises; he also served in their Pharmacy Quality council (P&T Committee).
Siva has a Master’s in Bioengineering from University of Strathclyde, UK, Master’s in Healthcare Finance and Management from Johns Hopkins University, USA, and Ph.D. in Business Research from Monarch University, Switzerland.
Siva continues to reach out to his network of relationships with public sector stakeholders, payers (U.S & Ex-U.S), HTA stakeholders, international/national societies, KOLs and Patient Advocacy Groups and publish insights relevant to them.
Siva built a strong career and leadership in commercial/medical strategies, market access, value/evidence and health policy within Pharma/Biotech industry through tenures at PTC Therapeutics (orphan diseases), Human Genome Sciences/GSK (orphan disease & immunology), BMS (oncology & immunology) and Merck & Co. (CNS, ID & respiratory) covering US & Ex-US segments. At PTC, as VP and Global Head, led market access, pricing and value creation department covering Americas, Europe, MENA & APAC.
In the strategy consulting arena, most recently, Siva was President and Global Head of Pointe Health/Pointe Advisory, a strategy consulting and competitive intelligence firm. Previously, Siva held SVP roles at DRG, TNS Healthcare/Kantar and Ipsos Healthcare leading relevant divisions and client strategies to help clients create commercial and scientific strategies and patient access solutions, articulate product value propositions and achieve optimal access in the U.S and Ex-U.S. Within healthcare provider sector, Siva led clinical and strategic evaluations across a spectrum of LTC services at Beverly Enterprises; he also served in their Pharmacy Quality council (P&T Committee).
Siva has a Master’s in Bioengineering from University of Strathclyde, UK, Master’s in Healthcare Finance and Management from Johns Hopkins University, USA, and Ph.D. in Business Research from Monarch University, Switzerland.
Siva continues to reach out to his network of relationships with public sector stakeholders, payers (U.S & Ex-U.S), HTA stakeholders, international/national societies, KOLs and Patient Advocacy Groups and publish insights relevant to them.
CONSULTING MEDICAL DIRECTOR
Todd Schlesinger, MD, FAAD
A dermatologist and researcher with extensive clinical, academic, and pharmaceutical experience, Dr. Todd Schlesinger has built a distinguished career in dermatology and therapeutic research. His work spans clinical practice, academic leadership, and collaboration with the pharmaceutical industry to advance dermatological innovation and patient care.
Dr. Schlesinger has held leadership roles at Epiphany Dermatology and the Clinical Research Center of the Carolinas in Charleston, South Carolina. In addition, he is a Clinical Assistant Professor of Dermatology at The George Washington University of Medicine and Health Sciences, an Affiliate Assistant Professor at the Medical University of South Carolina, and a Clinical Preceptor at MUSC’s College of Health Professions. He also serves as Clinical Faculty at the Edward Via College of Osteopathic Medicine.
Throughout his career, Dr. Schlesinger has focused on managing complex dermatological conditions, including acne, actinic keratosis, atopic dermatitis, cutaneous squamous cell carcinoma, cutaneous T-cell lymphomapsoriasis, hidradenitis suppurativa, cutaneous lymphomas, vitiligo , psoriatic arthritis, rosacea, and seborrheic dermatitis. His expertise extends to rare diseases such as necrobiosis lipoidica and prurigo nodularis, where he has contributed to innovative treatment strategies.
In the pharmaceutical research arena, Dr. Schlesinger has collaborated with leading companies, including AbbVie, Amgen, Athenex, Eli Lilly, Genentech, GSK, Pfizer, Regeneron, Sanofi, Novartis, and several smaller biotechs, participating in clinical trials that have advanced therapeutic options across dermatology and immunology. His work bridges scientific discovery and practical application, ensuring that patients benefit from cutting-edge advancements in the field.
Dr. Schlesinger earned his B.A. in Economics and M.D. from the School of Medicine and Biomedical Sciences at SUNY, Buffalo, NY. He is board-certified in dermatology and holds active medical licenses in Florida, Pennsylvania, and South Carolina.
Dr. Schlesinger continues to engage with academic, clinical, and research communities, working closely with public and private stakeholders to advance dermatological care. Through his dedication to education, clinical innovation, and research excellence, he remains at the forefront of improving patient outcomes in dermatology.
Dr. Schlesinger has held leadership roles at Epiphany Dermatology and the Clinical Research Center of the Carolinas in Charleston, South Carolina. In addition, he is a Clinical Assistant Professor of Dermatology at The George Washington University of Medicine and Health Sciences, an Affiliate Assistant Professor at the Medical University of South Carolina, and a Clinical Preceptor at MUSC’s College of Health Professions. He also serves as Clinical Faculty at the Edward Via College of Osteopathic Medicine.
Throughout his career, Dr. Schlesinger has focused on managing complex dermatological conditions, including acne, actinic keratosis, atopic dermatitis, cutaneous squamous cell carcinoma, cutaneous T-cell lymphomapsoriasis, hidradenitis suppurativa, cutaneous lymphomas, vitiligo , psoriatic arthritis, rosacea, and seborrheic dermatitis. His expertise extends to rare diseases such as necrobiosis lipoidica and prurigo nodularis, where he has contributed to innovative treatment strategies.
In the pharmaceutical research arena, Dr. Schlesinger has collaborated with leading companies, including AbbVie, Amgen, Athenex, Eli Lilly, Genentech, GSK, Pfizer, Regeneron, Sanofi, Novartis, and several smaller biotechs, participating in clinical trials that have advanced therapeutic options across dermatology and immunology. His work bridges scientific discovery and practical application, ensuring that patients benefit from cutting-edge advancements in the field.
Dr. Schlesinger earned his B.A. in Economics and M.D. from the School of Medicine and Biomedical Sciences at SUNY, Buffalo, NY. He is board-certified in dermatology and holds active medical licenses in Florida, Pennsylvania, and South Carolina.
Dr. Schlesinger continues to engage with academic, clinical, and research communities, working closely with public and private stakeholders to advance dermatological care. Through his dedication to education, clinical innovation, and research excellence, he remains at the forefront of improving patient outcomes in dermatology.
GLOBAL REACH
Assess and Execute
Globally
We work across the continents, leveraging our access to consumers (including patients and caregivers), healthcare professionals, payer/HTA stakeholders, and C-suite individuals within healthcare organizations, via existing stakeholder panels, proprietary networks and nurtured relationships. Our public health, marketing and scientific research services leverage these networks to deliver robust solutions and formulate strategic recommendations.
GLOBAL REACH
Access to >2 Million Healthcare Professionals
> 500,000 in Europe
> 450,000 in North America
> 30 specialties and sub-specialties
Quantitative and qualitative research
Bespoke site-based research
Medical chart reviews
> 450,000 in North America
> 30 specialties and sub-specialties
Quantitative and qualitative research
Bespoke site-based research
Medical chart reviews
GLOBAL REACH
Access to >17 Million Consumers
>6 Million in Europe
>6 Million in North America
>5 Million in Rest of the World
> 50 disease categories and segments
Quantitative and qualitative research
>6 Million in North America
>5 Million in Rest of the World
> 50 disease categories and segments
Quantitative and qualitative research
GLOBAL REACH
Access to >1000 Payer & HTA Stakeholders
Across Americas, Europe, and APAC
Advisory boards
Quantitative surveys in the U.S
Qualitative research in all markets
Advisory boards
Quantitative surveys in the U.S
Qualitative research in all markets
